...
首页> 外文期刊>Cardiovascular and Interventional Radiology: A Journal of Imaging in Diagnosis and Treatment >Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis.
【24h】

Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis.

机译:radi动脉入路用于急性广泛门脉和肠系膜上静脉血栓形成患者的经导管选择性肠系膜上动脉尿激酶输注治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this investigation was to assess the feasibility and effectiveness of transradial approach for transcatheter superior mesenteric artery (SMA) urokinase infusion therapy in patients with acute extensive portal and superior mesenteric venous thrombosis. During a period of 7 years, 16 patients with acute extensive thrombosis of the portal (PV) and superior mesenteric veins (SMV) were treated by transcatheter selective SMA urokinase infusion therapy by way of the radial artery. The mean age of the patients was 39.5 years. Through the radial sheath, a 5F Cobra catheter was inserted into the SMA, and continuous infusion of urokinase was performed for 5-11 days (7.1 +/- 2.5 days). Adequate anticoagulation was given during treatment, throughout hospitalization, and after discharge. Technical success was achieved in all 16 patients. Substantial clinical improvement was seen in these 16 patients after the procedure. Minor complications at the radial puncture site were observed in 5 patients, but trans-SMA infusion therapy was not interrupted. Follow-up computed tomography scan before discharge demonstrated nearly complete disappearance of PV-SMV thrombosis in 9 patients and partial recanalization of PV-SMV thrombosis in 7 patients. The 16 patients were discharged 9-19 days (12 +/- 6.0 days) after admission. Mean duration of follow-up after hospital discharge was 44 +/- 18.5 months, and no recurrent episodes of PV-SMV thrombosis developed during that time period. Transradial approach for transcatheter selective SMA urokinase infusion therapy in addition to anticoagulation is a safe and effective therapy for the management of patients with acute extensive PV-SMV thrombosis.
机译:这项研究的目的是评估经radi动脉入路治疗急性广泛性门脉和肠系膜上静脉血栓形成的患者的经导管肠系膜上动脉(SMA)尿激酶输注治疗的可行性和有效性。在7年的时间里,对16例急性门脉广泛血栓形成(PV)和肠系膜上静脉(SMV)的患者通过radial动脉经导管选择性SMA尿激酶输注治疗。患者的平均年龄为39.5岁。通过the骨鞘,将5F Cobra导管插入SMA,并连续输注尿激酶5-11天(7.1 +/- 2.5天)。在治疗期间,整个住院期间和出院后给予足够的抗凝治疗。全部16例患者均获得技术成功。手术后这16例患者可见明显的临床改善。在5例患者中观察到the骨穿刺部位的轻微并发症,但是经SMA输注治疗并未中断。出院前的后续计算机断层扫描显示,9例患者的PV-SMV血栓形成几乎完全消失,7例患者的PV-SMV血栓形成部分再通。入院后9-19天(12 +/- 6.0天)出院的16例患者。出院后的平均随访时间为44 +/- 18.5个月,在此期间没有复发性PV-SMV血栓形成。经anti动脉除抗凝外,经导管选择性SMA尿激酶输注疗法是一种治疗急性广泛PV-SMV血栓形成患者的安全有效的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号